Company Participants
Andrew McKibben – Senior Vice President, Strategic Finance & Investor Relations
Christopher Peetz – CEO & Director
Peter Radovich – COO & President
Rob Myers – Chief Medical Officer
Eric Bjerkholt – Chief Financial Officer
Conference Call Participants
Joshua Schimmer – Cantor Fitzgerald & Co., Research Division
Luke Herrmann – Robert W. Baird & Co. Incorporated, Research Division
Yesha Patel – Evercore ISI Institutional Equities, Research Division
Kalpit Patel – Wolfe Research, LLC
Ryan Deschner – Raymond James & Associates, Inc., Research Division
James Condulis – Stifel, Nicolaus & Company, Incorporated, Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Michael Ulz – Morgan Stanley, Research Division
Lisa Walter – RBC Capital Markets, Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Charles Wallace – H.C. Wainwright & Co, LLC, Research Division
Joseph Thome – TD Cowen, Research Division
Presentation
Operator
[Operator Instructions] Good afternoon, and welcome to Mirum Pharmaceuticals Third Quarter 2026 Earnings Conference Call. My name is Joel, and I will be your operator today. [Operator Instructions] I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.
Andrew McKibben
Senior Vice President, Strategic Finance & Investor Relations
Thank you, Joel, and good afternoon, everyone. I’d like to welcome you to Mirum Pharmaceuticals Third Quarter 2026 Conference Call. I’m joined today by our Chief Executive Officer, Chris Peetz; our President and Chief Operating Officer, Peter Radovich; our Chief Medical Officer, Rob Myers; and our Chief Financial Officer, Eric Bjerkholt.
Earlier today, Mirum issued a press release announcing the company’s results for the third quarter of 2026. Copies of the press release and our SEC filings are available on the